Transgenic,cross-linked hemoglobin
AssigneeThe UAB Research Foundation
InventorsTim M. Townes, Steven L. McCune
Life of this patent
Estimating the term…
Abstract
Transgenic, recombinantly cross-linked polymeric human hemoglobins suitable as cell-free blood substitutes have been produced. A plurality of DNA constructs have been designed for efficient expression of modified human hemoglobins in the erythrocytes of the non-human transgenic animals. Substantially pure, non-immunogenic, artificial human hemoglobins are then easily obtained from the erythroid cells of the transgenic animals.
Claims9
A transgenic, recombinantly produced, polymeric human hemoglobin molecule having a recombinantly-introduced cysteinyl residue which forms an intramolecular disulfide bridge, said disulfide bridge being formed between .beta.1 1 to .beta.2 146.
A transgenic, recombinantly produced, polymeric human hemoglobin molecule having a recombinantly-introduced cysteinyl residue which forms an intramolecular disulfide bridge, said disulfide bridge being formed between .alpha.1 130 to a cysteinyl residue added to the carboxy terminus of .alpha.2 142.
A transgenic, recombinantly produced, polymeric human hemoglobin molecule having a recombinantly-introduced cysteinyl residue which forms an intermolecular disulfide bridge, said cysteinyl residue being introduced by replacing .alpha.1 aspartic acid 75 with cysteine or by replacing .beta.9 serine with cysteine.
A transgenic, recombinantly produced human hemoglobin molecule comprising the Hemoglobin Kansas mutation in the .beta. chain at Asn102Thr and the Hemoglobin Porto Alegre mutation in the .beta. chain at Ser9Cys.
A transgenic, recombinantly produced human hemoglobin molecule comprising two or three polymerized hemoglobin tetramers, each said tetramer having the Hemoglobin Porto Alegre mutation in the .beta. chain at Ser9Cys and replacing the two amino-terminal .beta.-chain amino acids with methionine or another hydrophobic amino acid.
Dependencies are inferred from the claim text.